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Ryanodine receptors (RyR) regulate intracellular Ca2+ release in many cell types and have been
implicated in a number of inherited human diseases. Over the past 15 years genetically engineered
mouse models have been developed to elucidate the role that RyRs play in physiology and patho-
physiology. To date these models have implicated RyRs in fundamental biological processes includ-
ing excitation–contraction coupling and long term plasticity as well as diseases including malignant
hyperthermia, cardiac arrhythmias, heart failure, and seizures. In this review we summarize the RyR
mouse models and how they have enhanced our understanding of the RyR channels and their roles
in cellular physiology and disease.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
RyRs are a family of intracellular Ca2+ release channels that
mediate the release of Ca2+ from the sarco/endoplasmic reticulum
(S/ER). RyR1 and RyR2 are found predominantly in skeletal and
cardiac muscle, respectively, where they play a central role in exci-
tation–contraction coupling [1–3]. RyR3 is also expressed in skele-
tal muscle at a low level [4], though its physiologic role there is
unclear. All three isoforms are expressed in the mammalian brain.
RyR1 is enriched in Purkinje cells of the cerebellum, RyR2 is pre-
dominantly expressed in the dentate gyrus of the hippocampus
[5], and RyR3 has been detected in the hippocampal CA1 pyramidal
cell layer, the basal ganglia, and olfactory bulbs [6]. RyR2 is also
found in pancreatic islets [7] and RyR1 and RyR3 have been re-
ported in leukocytes [8,9]. All three isoforms are present in smooth
muscle cells [10] (Fig. 1).
RyR1 cDNA was originally cloned in 1989 from rabbit fast
twitch skeletal muscle [11,12] and later by a third group in 1990
[13]. In 1990 RyR2 cDNA was sequenced from rabbit heart
[14,15] and 2 years after that the cDNA of RyR3 was cloned from
a rabbit brain cDNA library [16]. All RyR isoforms exist as homotet-
ramers composed of four 565 kDa subunits, with the N-terminal
4/5 of the channel comprising an enormous cytoplasmic domain
that serves as a scaffold for proteins that regulate the channel func-
tion, and the remaining 1/5 in the SR lumen [17]. Studies in whichchemical Societies. Published by E
Pavilion, Room 520, 1150, St.
851 5345.
).truncated RyR was recombinantly expressed and then reconsti-
tuted in planar lipid bilayers have identiﬁed the 1030 C-terminal
amino acids as capable of forming a channel thereby indicating
that the transmembrane regions of the channel are likely included
in this region [18]. However, it remains unclear as to how many
transmembrane segments exist in the RyR channels with the pre-
vailing view being that there are six for each monomer but possibly
as many as eight [19]. The three isoforms share 65% homology
with most of the sequence disparity clustered in three divergent
regions referred to as D1, D2, and D3 [17].
Excitation–contraction (EC) coupling in mammalian skeletal
muscle is initiated by depolarization of the surface membrane (sar-
colemma), which causes conformational changes in plasma mem-
brane Cav1.1 Ca2+ channels (L-type Ca2+ channels or LTCC). This
leads to activation of closely apposed RyR1 channels found on
the terminal cisternae of the SR resulting in the rapid release of
Ca2+ from the SR into the cytosol. Ca2+ binds to troponin C enabling
the formation of cross bridges between actin and myosin ﬁlaments
and sarcomere shortening. A direct interaction between amino acid
residues 1837–2168 on rabbit RyR1 and a portion of the a1S II–III
loop on Cav1.1, is thought to allow for communication between
the two channels during EC-coupling [20]. Activation of LTCC also
mediates mammalian cardiac EC-coupling, albeit through a differ-
ent mechanism. T-tubule depolarization leads to Ca2+ entry
through Cav1.2 and, in a process known as Ca2+ induced Ca2+ re-
lease (CICR), Ca2+ binds to RyR2 leading to activation of the channel
and release of SR Ca2+ stores. After contraction in both skeletal and
cardiac muscle, Ca2+ is pumped back into the SR through sarco/
endoplasmic reticulum ATPase (SERCA) [21].lsevier B.V. All rights reserved.
Fig. 1. Genetically modiﬁed mouse lines discussed in this review with the RyR targeted mutations highlighted to their respective region of the channel.
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lated by enzymes targeted to the channel cytoplasmic domain as
well as physiological activators and inhibitors [17]. Ca2+, the most
important activator of RyR, activates RyR1–3 at concentrations in
the low hundreds of nanomolar [22] and is responsible for RyR2
activation in the heart and ampliﬁcation of RyR1 Ca2+ release in
skeletal muscle [3]. At higher concentrations (1 mM) Ca2+ inhibits
RyR1 but has less of an inhibitory affect on RyR2 and RyR3 [3].
Whether or not the inhibitory effects of Ca2+ on RyRs exist to pre-
vent positive feedback on RyRs (i.e. Ca2+ released from RyR would
continuously activate the channels and prevent them from closing)
remains contentious [3,23].
Magnesium inhibits RyR activity, either by competing with Ca2+
or by binding to speciﬁc inhibition sites [24,25]. Calmodulin (CaM),
a 17 kDa Ca2+ binding protein, binds to RyR1 at Cys3635 [26] and
to the corresponding region on RyR2, 3578–3603 [27]. CaM can
either activate or inhibit RyR1 depending on Ca2+ concentrations
[28] but appears to preferentially inhibit RyR2 [29]. The RyR cyto-
solic N-terminal region contains leucine–isoleucine zipper motifs,
that function as speciﬁc anchoring sites for muscle A-kinase-
anchoring protein (mAKAP), which targets PKA and phosphodies-
terase 4D3 (PDE4D3) to the channel, as well as for spinophilin
and PR130, which target the protein phosphatases PP1 and PP2A
to RyR2, respectively [30]. The 12 and 12.6 kDa FK506 binding pro-
teins (FKBP12 and FKBP12.6) bind to and stabilize the closed state
of RyR1 [31] and RyR2 [32], respectively, and are essential for cou-
pled gating of RyR channels [33,34]. Now that cellular functions for
FKBP12 and FKBP12.6 as components of the RyR1 and RyR2 macro-
molecular complexes have been identiﬁed we have proposed
renaming them as calcium channel stabilizing binding proteins,
Calstabin1 and Calstabin2, respectively [35]. Ca2+/CaM-dependent
protein kinase II (CaMKII) associates with, phosphorylates, and reg-
ulates the activity of RyR in the heart [36] and skeletal muscle [37].
Junctin, triadin, and calsequestrin form a complex with the luminal
C-terminus of RyR [38]. Calsequestrin, a low afﬁnity, high capacity
luminal Ca2+ buffering protein regulates local Ca2+ levels near the
RyR pore and may also directly modulate RyR activity [38]. Triadin,an integral SR membrane protein, is important for proper orienta-
tion and activity of the RyR-LTCC Ca2+ release unit (CRU) in both
cardiac and skeletal muscle, as triadin deﬁcient mice have a 50%
reduction in the number of CRUs and those remaining are frag-
mented, lacking proper SR – T-tubule contact [39,40]. Junctin, an
integral SR membrane protein, may play a role in modulating the
regulatory action of calsequestrin on RyR1 in skeletal muscle and
has been demonstrated to stabilize RyR2 in myocardium using
junctin deﬁcient mice [41]. Sorcin has been proposed to interact
with RyR to reduce EC-coupling gain and help terminate CICR
[42] (Fig. 2).
2. Skeletal muscle
That depolarization of the sarcolemma induces skeletal muscle
contraction via SR Ca2+ release through RyR1 was originally dem-
onstrated pharmacologically using the RyR blocker ryanodine
[43]. The earliest animal data supporting this model came from
the RyR1 skrrm1 mouse, which was engineered lacking exon 2 of
Ryr1 and expresses non-functional RyR1 [1]. Homozygous skrrm1
mice have severe skeletal muscle abnormalities and die perinatally
due to respiratory failure, based on the observation that the pups
fail to breathe and appear cyanotic after birth.
Isolated neonatal skeletal muscle from the skrrm1/skrrm1 mice
does not contract in response to electrical stimulation, but does
contract in response to caffeine [1], a pharmacological activator
of RyRs. The caffeine response is abolished in RyR1/RyR3 double
knockout mice suggesting that RyR3 is functionally expressed in
neonatal skeletal muscle and is responsible for the residual caf-
feine response observed in the RyR1 skrrm1 skeletal muscle
[44,45]. RyR3 expression in skeletal muscle has been shown to de-
cline with age [46] and neonatal but not adult RyR3 knockout mice
exhibit impaired skeletal muscle function [47], further supporting
the idea that RyR3 plays a more substantial role in neonatal as op-
posed to adult skeletal muscle. Electron microscopic studies of iso-
lated hind limb and diaphragm muscles show that skrrm1/skrrm1
mice are ‘‘dyspedic” (lack the cytosplasmic domains of RyR called
Fig. 2. Cardiac excitation–contraction coupling. Ca2+ entry through LTCC activates RyR2 to release sarcoplasmic reticulum (SR) Ca2+ stores into the cytosol where the Ca2+
binds to myoﬁlaments leading to cell shortening and cardiac contraction. Ca2+ is subsequently pumped back into the SR through SERCA and out of the cell through the
sodium–calcium exchanger and the plasmalemmal Ca2+ pump. RyR2 is a homotetramer regulated by many proteins (for simplicity these proteins are depicted here on only
one RyR monomer).
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ing additional evidence that these structures play key roles in skel-
etal muscle EC-coupling.
The ability to reconstitute recombinant RyR in the dyspedic
myotubes isolated from the RyR1 deﬁcient mice has helped eluci-
date several RyR related processes including the crosstalk between
RyR1 and Cav1.1 [49], diseases associated with RyR1 mutations
[50], as well as the effect of modulatory proteins such as CaM on
RyR1 [51]. For example, myotubes isolated from RyR1 deﬁcient
mice have a 40% reduction in the surface expression of Cav1.1 with
the remaining channels exhibiting reduced Ca2+ conductance as
well as altered kinetics in response to the Cav1.1 activator Bay K
8644 [52]. Transfection of these myotubes with recombinant
RyR1 restores Cav1.1 function back to normal [49] indicating that
RyR1 acts as an allosteric modulator of Cav1.1 [53].
Transgenic RyR1 mice have helped elucidate the pathophysiol-
ogy of malignant hyperthermia (MH), a pharmacogenetic condition
whereby a mutation carrying patient who receives a volatile anes-
thetic suddenly deteriorates into a hypermetabolic state with skel-
etal muscle contracture and hyperthermia. More than 90
mutations in RyR1 are linked to MH susceptibility. MH is believed
to be caused by anesthesia induced dysregulation of myoplasmic
Ca2+ handling and that the efﬁcacy of dantrolene, the only drug
available for treating MH, is based on its ability to inhibit RyR1
and stabilize Ca2+ levels [50].
Mice homozygous for the RyR1-Y522S mutation, a mouse mod-
el of MH, die between embryonic day 17.5 and postnatal day 1 and
have marked skeletal abnormalities [54]. Heterozygous mice are
born without any overt defects and develop MH when exposed
to isoﬂurane (a volatile anesthetic), as characterized by full body
contracture and elevated body temperature. Skeletal muscle iso-
lated from heterozygous mice has increased sensitivity to caffeinesuggesting that the lethal phenotype imparted by this mutation
may be related to higher sensitivity of RyR1 to cytosolic Ca2+
resulting in RyR1 openings during rest, referred to as SR Ca2+ leak.
The RyR1-Y522S mice have helped elucidate a putative patho-
physiological mechanism for heat stroke [55]. Skeletal muscle
myocytes isolated from the RyR1-Y522S mice have increased SR
Ca2+ leak, which leads to the generation of reactive nitrogen spe-
cies and S-nitrosylation of RyR1, which further enhances SR Ca2+
leak through RyR1. This feed forward process results in increased
temperature sensitivity of RyR1 for activation causing muscle con-
tractures upon exposure to elevated temperatures and eventual
mitochondrial damage and myopathy.
The RyR1-R163C mice are another model of MH [56]. Homozy-
gous R163C mice are embryonically lethal while heterozygous
mice are viable and develop MH when exposed to low doses of
vaporized halothane. None of the R163C mice develop signs of
MH when pretreated with dantrolene. Myotubes isolated from
both homozygous and heterozygous R163C knock-in mice have in-
creased sensitivity to caffeine similar to that observed in the Y522S
mice. However, in contrast to the normal baseline Ca2+ levels in
heterozygous Y522S mice, the resting Ca2+ levels in heterozygous
R163C mice are elevated compared to control mice suggesting that
the R163Cmutation located nearer to the N-terminus of RyR1 has a
greater affect on Ca2+ gating and leak.
Mutations in RyR1 have also been linked to central core disease
(CCD), a congenital myopathy characterized by poor muscle tone,
muscle weakness, and musculoskeletal abnormalities throughout
infancy and adulthood [50]. Mice engineered with one of these
mutations, RyR1-I4895T, die shortly after birth due to cyanosis sec-
ondary to severe skeletal muscle abnormalities [57]. Histologically,
skeletal muscle isolated from these mice is not robustly striated
and exhibit poorly aligned myotubes. Myotubes isolated from
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normal SR load and no SR Ca2+ leak, suggesting that the pathophys-
iology of this CCD mutation is linked to defects in Cav1.1 induced
activation of RyR1 (un-coupling) rather than leaky RyR1 [57].
These mice have normal retrograde coupling of RyR1 and Cav1.1
suggesting that orthograde and retrograde communication be-
tween RyR1 and Cav1.1 operate through independent pathways.
3. Heart
The primary role that RyRs play in cardiac CICR and EC-coupling
was originally demonstrated using ryanodine [58], which was
found to reduce contractility by blocking SR Ca2+ release [59].
The development of an RyR2 knockout mouse, which is embryon-
ically lethal and whose cardiomyocytes lack SR Ca2+ release, pro-
vides additional evidence that this isoform is the major source of
SR Ca2+ release during cardiac EC-coupling [2].
Despite the central role that Ca2+ release via RyR2 plays in
mammalian cardiac EC-coupling the role that physiologic modula-
tion of RyR2 has in homeostasis is less clear. One hypothesis, that
PKA phosphorylation of RyR2 is a downstream mediator of the
‘‘ﬁght or ﬂight” response has generated signiﬁcant controversy.
During the normal sympathetic response norepinephrine is re-
leased from sympathetic nerve terminals and binds to and stimu-
lates the b1-adrenergic receptor, a G-protein coupled receptor,
leading to activation of PKA. PKA subsequently phosphorylates
many Ca2+ handling proteins including LTCC, phospholamban
(PLN), and RyR2, generally resulting in faster Ca2+ transients with
higher amplitude [21]. PKA phosphorylation of PLN at Ser16 re-
lieves its inhibitory effect on SERCA and consequently accelerates
SR Ca2+ loading [60], while PKA phosphorylation of RyR2 at
Ser2808 increases RyR2 open probability, which can potentially in-
crease SR Ca2+ release [17]. However, while transgenic mice with
PLN that cannot be PKA phosphorylated have a blunted cardiac re-
sponse to b1-adrenergic stimulation [60], it has been reported that
mice with an RyR2-S2808A mutation have largely normal re-
sponses [61,62], however these results have been disputed. Indeed,
evidence exists that modulation of RyR2 plays a role in the re-
sponse to b1-adrenergic stimulation [63,64], warranting further
investigations as to whether these RyR2 phosphorylation modu-
lates peak Ca2+ transient amplitude and cardiac contractility [65].
The existence and functional signiﬁcance of an alternate RyR2
PKA site at Ser2030 is also controversial [62,66–68].
CaMKII dependent phosphorylation of RyR2 at Ser2814 has also
been shown to increase the Ca2+ sensitivity and open probability of
RyR2 [17] leading to the idea that the ‘‘ﬁght or ﬂight” response is
mediated by b1-adrenergic activation of CaMKII and subsequent
phosphorylation of RyR2. The recent development of the RyR2-
S2814A transgenic mouse harboring RyR2 lacking the major CaM-
KII phosphorylation site, will help elucidate this hypothesis [69].
The RyR2-S2814A mouse will also make it possible to test whether
CaMKII dependent phosphorylation of RyR2 is involved in the force
frequency response (FFR). Since the late 19th century it has been
observed that cardiac contractility increases as a function of con-
tractile frequency. The ability of CaMKII to sense the frequency of
Ca2+ oscillations has led to the hypothesis that frequency depen-
dent activation of CaMKII and phosphorylation of RyR2 at
Ser2814 contributes to the FFR [70].
Heart failure is a syndrome characterized by the inability of the
heart to produce sufﬁcient cardiac output to meet the metabolic
needs of the organs. A hallmark of heart failure is elevation of cir-
culating catecholamines, which leads to persistent stimulation of
the b1-adrenergic receptor. Our laboratory has reported that PKA
hyperphosphorylation of RyR2 at Ser2808, and depletion of calsta-
bin2 from the channel results in defective RyR2 channels that leak
SR Ca2+ contributing to heart failure progression [32] and arrhyth-mias [71]. The term ‘‘PKA hyperphosphorylation” refers to RyR2
with three to four of the four monomers that comprise this homo-
tetrameric channel phosphorylated by PKA. Depletion of calstabin2
causes increased diastolic leak through the channel [71], leading to
depletion of SR Ca2+ stores and reduced contractility [72]. Diastolic
leak increases ITI (transient inward current) through the Na+/Ca2+
exchanger (NCX), which leads to delayed-after-depolarizations
(DADs) [71,73] that can trigger ventricular arrhythmias. In support
of these ﬁndings, RyR2-S2808A knock-in mice, which cannot be
PKA phosphorylated on RyR2, exhibited signiﬁcantly improved car-
diac contractility compared with control mice at 28 days post-
myocardial infarction (MI) [66].
Other laboratories, however, have not been able to demonstrate
that depletion of calstabin2 from RyR2 induces changes in channel
function [74] or that PKA phosphorylation causes dissociation of
calstabin1 or 2 from RyR1 or 2, respectively [75,76]. In several in-
stances the explanation for the differences in the results may be
due to altered stoichiometry of calstabin and RyR (i.e. addition of
molar excesses of calstabin to the immunoprecipitation reactions)
[76]. Of particular interest is the observation by Hamilton and col-
leagues [77], later conﬁrmed by our own studies [78], that nitrosy-
lation of RyR1 can cause dissociation of calstabin1 from the
channel. Additionally, oxidation of RyR2 has been shown to disrupt
calstabin2 binding to the channel [79] and contribute to heart fail-
ure progression [80]. This raises the possibility that the status of
nitrosylation and oxidation of the channel may vary from experi-
ment to experiment. As this is a factor that is not typically as-
sessed, differences in nitrosylation or oxidation of the RyR
channels could add to the variability of these types of experiments
and explain some of the inability of other laboratories to reproduce
our ﬁndings. In other instances it appears that the inability to
reproduce our results may in actuality be explained simply by dif-
ferences interpretation of the data. For example, in another study,
despite concluding that the RyR2-S2808Amutation does not confer
cardioprotection against cardiomyopathy, the investigators re-
ported that control mice with cardiomyopathies, induced by aortic
banding, exhibited a 20% reduction in cardiac fractional shortening
(FS), whereas the RyR2-S2808A mice had no decrease in FS [62,65],
and therefore were protected against progression of cardiac dys-
function in agreement with our ﬁndings [66].
Animal data supporting the hypothesis that depletion of calsta-
bin2 from RyR2 increases susceptibility to arrhythmias comes from
the calstabin2/ and calstabin2+/ mice, which have increased
rates of exercise-induced sudden cardiac death (SCD) [71] and
atrial ﬁbrillation [81]. This increased incidence of SCD can be
eliminated in calstabin2+/ mice treated with JTV519, a 1,4-ben-
zothiazepine that facilitates the re-association of calstabin2 to
RyR2. Although some investigators using cellular based studies
have suggested that the cardioprotective effects of JTV519 are
mediated through pathways independent of calstabin2 [82] in
our in vivo studies we found that JTV519 was not effective in pre-
venting SCD in calstabin2/mice indicating that the drug requires
calstabin2 for its mechanism of action in the heart [83]. Addition-
ally, control mice treated with JTV519 had improved contractility
post-MI while calstabin2/mice did not [72]. On the cellular level,
cardiomyocytes isolated from calstabin2/ mice have increased
Ca2+ spark amplitude and size [84] and greater SR Ca2+ leak [81].
Other laboratories have similarly reported that calstabin2 deﬁ-
ciency is linked to enhanced susceptibility to arrhythmias
[81,85,86]. However, once again others have not been able to
reproduce these results [74,87]. As is often the case with in vivo
studies, differences in the conditions used to elicit the arrhythmias
are the most likely explanation for the ability of some groups but
not others to observe stress induced arrhythmias in the calstabin2
deﬁcient mice. In addition, differences in genetic background often
cause phenotypic differences in mice. In our studies mice are back-
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ensure that all genetically altered mice are evaluated in the same
genetic background. In the study that reported no increased sus-
ceptibility to arrhythmias in a calstabin2 deﬁcient mouse model
there was no mention of the genetic background of the mice
[74]. These conﬂicting reports highlight the fact that animal mod-
els, while helpful, do not necessarily always solve controversies.
Constitutive CaMKII phosphorylation of RyR2 has also been
hypothesized to play a role in the pathogenesis of heart failure.
This is based on observations that transgenic mice overexpressing
CaMKII have increased CaMKII dependent phosphorylation of RyR2
and develop cardiac hypertrophy as well as signs of dilated cardio-
myopathy [88]. Additionally, CaMKII delta deﬁcient mice are pro-
tected against pressure overload induced cardiomyopathy [89]. It
is believed that the hyperadrenergic state induced by these condi-
tions leads to chronic activation of b-adrenergic receptors leading
to downstream activation of CaMKII, which then phosphorylates
RyR2, causing a diastolic leak through the channel, resulting in de-
pleted SR Ca2+ stores and reduced cardiac function.
A role for CaMKII phosphorylation of RyR2 in arrhythmias
comes from a study showing that atria from patients with AF have
elevated levels of activated CaMKII and increased phosphorylation
of RyR2 at Ser2815 (corresponding to Ser2814 in mice) [69]. Fur-
thermore, mice engineered with a RyR2-S2814A mutation have
been reported to be protected from developing AF when exposed
to high frequency pacing, which activates CaMKII, in the presence
of the cholinomimetic carbachol [69].
CaM regulation of RyR2 may play an important role in prevent-
ing cardiomyopathy and heart failure. The RyR2-W3587A/L3591D/
F3603A (RyR2-ADA) knock-in mice, which have an altered CaM
binding domain on RyR2, develop left ventricular hypertrophy
shortly after birth and begin to die around post natal day 10
[27]. The investigators in this study attributed the hypertrophy
and death to enhanced phosphorylation of class II histone deacet-
ylases (HDACs) by an unidentiﬁed Ca2+ dependent kinase, which
leads to increased activity of growth related transcription factors.
The inability of CaM to assist in terminating systolic RyR2 Ca2+ re-
lease in the mutant mice leads to prolonged Ca2+ transients and
elevated cytosolic [Ca2+], which activates the kinases responsible
for phosphorylating the HDACs [27].
Transgenic RyR2 mice have helped elucidate the pathophysiol-
ogy of a pair of rare familiar arrhythmias: catecholaminergic poly-
morphic ventricular tachycardia (CPVT) and arrhythmogenic right
ventricular dysplasia type 2 (ARVD2). Patients carrying CPVT
mutations have no signs or symptoms at baseline but are at in-
creased risk for exercise induced sudden cardiac death (often the
presenting symptom). In ARVD, these arrhythmias are associated
with ﬁbrofatty replacement of the right ventricle [17]. To date
more then 70 mutations in three regions of RyR2 have been found
in patients with CPVT and ARVD. RyR2 channels engineered with
some of these mutations have been studied in planar lipid bilayers
and exhibited normal open probabilities at diastolic [Ca2+]
(150 nM), but increased open probabilities under similar condi-
tions after PKA phosphorylation [71]. These results have led to
the hypothesis that activation of b1-adrenergic receptors during
exercise leads to PKA dependent phosphorylation of RyR2 that un-
masks a gain-of-function mutation in the channel, which combined
with the increased SR Ca2+ load due to higher activated PLN, leads
to diastolic leak, ITI, and DADs [71].
Support for this hypothesis comes from the RyR2-R2474S
mouse, which reproduces many aspects of human CPVT [90]. First,
homozygous mutants do not follow Mendelian inheritance pat-
terns after embryonic day 16.5 suggesting that this mutation can
cause intrauterine lethality. Moreover, the embryonic lethality
was prevented by treating the mothers with S107, a novel drug
similar to JTV519 that prevents diastolic SR Ca2+ leak via RyR2 byenhancing the binding afﬁnity of calstabin2 for the mutant chan-
nels [90]. At rest the RyR2-R2474S mice have normal heart rates
and rhythm, however when exercised and treated with epineph-
rine these mice developed bidirectional and polymorphic ventricu-
lar tachycardia, similar to patients with CPVT. Ventricular
cardiomyocytes isolated from these mice had increased ITI densi-
ties and Ca2+ sparks when treated with isoproterenol but not at
rest. Treating these mice with S107 reduced ITI density and the
incidence of ventricular tachycardias [90].
The RyR2-R4496C knock-in mouse is another animal model of
CPVT. These mice are different from the RyR2-R2474S mouse in
that they demonstrated a signiﬁcant increase in spontaneous
opening of RyR2 even in the absence of isoproterenol [91]. Addi-
tionally, SR microsomes isolated from these mice treated with epi-
nephrine showed no reduction in calstabin2 binding suggesting
that b1-adrenergic receptor activation does not cause dissociation
of calstabin2 from RyR2 [87]. Spark frequency in cardiomyocytes
isolated from these mice increased rapidly in response to increas-
ing Ca2+ concentrations compared to control mice [91] in agree-
ment with the concept that the underlying cause of arrhythmias
in this CPVT mutant is increased sensitivity of RyR2 to Ca2+ [71].
In this study the investigators suggest that the CPVT mutations in-
crease the sensitivity of RyR2 to luminal [Ca2+], as opposed to cyto-
solic [Ca2+], and that during exercise, stimulation of the b1-
adrenergic receptor pathway causes PKA dependent phosphoryla-
tion of PLN, increased SERCA activity, and increased SR Ca2+ load,
which leads to enhanced opening of RyR2 and increased SR Ca2+ ef-
ﬂux during diastole, causing DADs [91]. This hypothesis, store
overload induced calcium release (SOICR), was originally devel-
oped using a heterologous system whereby investigators observed
the number of cells exhibiting Ca2+ oscillations in response to pro-
gressively elevated SR Ca2+ stores [92]. In these studies the inves-
tigators found that HEK cells expressing recombinant RyR2
channels containing CPVT mutations were more sensitive to ele-
vated SR Ca2+ load then WT controls [92]. The observation that
the RyR2-R4496C mice have increased frequency of Ca2+ waves
and sparks at lower SR Ca2+ loads may support the SOICR hypoth-
esis [91].
Optical mapping studies using hearts from RyR2-R4496C mice
have been useful in elucidating the mechanism of arrhythmogen-
esis in CPVT [93]. The arrhythmias appear to originate within the
His-Purkinje conduction system and subsequently become reen-
trant tachycardias and ventricular ﬁbrillation. Patch clamp exper-
iments demonstrated that isolated Purkinje cells from the
mutant mice have a higher frequency of DADs that is exacer-
bated by application of isoproterenol [93]. It remains to be seen
whether other CPVT mouse models have similar conduction
abnormalities and whether PKA or CaMKII phosphorylation of
RyR2 plays a role.
CPVT mutations also exist in the central region of RyR2. To test
the effect of these mutations a mouse line with the RyR2-P2328S
CPVT mutation has been generated. These animals have sustained
runs of ventricular tachycardia when subjected to programmed
electrical stimulation protocols in the presence of isoproterenol.
Additionally, in the presence of isoproterenol, isolated cardiomyo-
cytes from the homozygous P2328S mice exhibited altered Ca2+
homeostasis, characterized by ectopic Ca2+ release peaks during
0.5 hz stimulation [94].
Dysruption of interdomain interactions within the RyR2 com-
plex has also been proposed as a mechanism underlying CPVT
[95]. In this model RyR2 channels with CPVT mutations have nor-
mal domain–domian interactions at baseline, however b-adrener-
gic stimulation leads to unzipping of these domains, which
causes the SR Ca2+ leak responsible for DADs [96]. Accordingly, it
has been suggested that JTV519 prevents SR Ca2+ leak by stabiliz-
ing the zipped state of the channel [96].
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ARVD2, has been more difﬁcult to reconcile with the human dis-
ease. RyR2-R176Q mice are similar to ARVD2 patients in that they
demonstrate right ventricular diastolic dysfunction and b-adrener-
gic receptor activation induced premature ventricular beats, how-
ever they have no overt histological changes [97]. One possible
explanation is that ARVD patients carrying the RyR2-R176Q muta-
tion also carry a RyR2-T2505M mutation and therefore it is possi-
ble that both mutations are required in order for overt histological
changes to develop.
Mutations in calsequestrin2 have also been linked to CPVT. Mice
engineered to express human CPVT mutations CASQ2-R33Q [98],
CASQ2-D307H, and CASQ2DE9 (truncated calsequestrin) [99] all ex-
hibit stress induced ventricular arrhythmias as well as reduced lev-
els of calsequestrin, due to decreased stability of the mutant
proteins. Cardiomyocytes isolated from these mice have enhanced
RyR2 mediated SR Ca2+ leak, as well as DADs [98,99], and EADs
[98]. Calsequestrin knockoutmice have normal baseline heart func-
tion and develop sustained runs of ventricular tachycardia during
exercise [100,101]. Cardiomyocytes isolated from these mice have
a left shifted SR leak/load relationship whereby a relatively low
SR Ca2+ load induces a large SR Ca2+ leak through RyR2. These data
suggest that arrhythmogenesis in CPVT patients carrying calse-
questrin mutations may be due to diminished calsequestrin depen-
dent modulation of RyR2 secondary to reduced total calsequestrin
protein levels and perhaps lower afﬁnity of calsequestrin to RyR2.
A putative role for RyR2 mediated Ca2+ release in automaticity
has been demonstrated in embryonic stem cell-derived cardio-
myocytes isolated from RyR2 deﬁcient mice, which lack spontane-
ous contractions [102]. These observations contribute to the
hypothesis that in sinoatrial node (SAN) cells SR Ca2+ release
through RyR2 activates the NCX producing an inward current that
accelerates the rate of spontaneous membrane depolarization that
drives the heart rate. As a corollary, phosphorylation of RyR2 by
either CaMKII [103] or PKAmaymediate the chronotropic response
observed during the ‘‘ﬁght or ﬂight” response.
4. Brain
Despite the presence of RyRs throughout the brain little is
known regarding their functional signiﬁcance in this organ. The
viability of the general RyR3 knockout mouse, in contrast to the
RyR1 and RyR2 knockout mice [1,2,104], has resulted in many
studies characterizing the neurological phenotype of these mice.
The RyR3 deﬁcient mice exhibit decreased social behavior [105]
and two times greater locomotor activity [104] that is associated
with the tendency to run in circular motions [6]. Striatum from
these mice release less dopamine when challenged with low con-
centration ryanodine, which activates ryanodine receptors, sug-
gesting the possibility that the effect of RyR3 on locomotion may
be related to its role in the basal ganglia [106].
Field recordings from the CA1 region of the hippocampus show
that RyR3 deﬁcient mice have impaired maintenance of long term
potentiation (LTP) [107] when induced by weak stimuli but are
similar to controls when LTP is induced via stronger stimulation
protocols [6]. These data suggest that RyR3 enhances LTP. Further
evidence that RyR3 enhances LTP comes from observations that
RyR3 deﬁcient mice have smaller AMPA receptor induced excit-
atory post-synaptic potentials (these events are an important com-
ponent of LTP) [107]. Other studies have shown that RyR3 deﬁcient
mice have a lower threshold for inducing LTP [108], suggesting that
RyR3 naturally inhibits LTP. Furthermore, LTP in RyR3 knockout
mice is NMDA independent and the absence of any compensatory
mechanisms has led to suggestions that the physiologic role of
NMDA receptor activation is to overcome the inhibitory effects of
RyR3 on LTP [108].In Morris water-maze RyR3 knockout mice form superior spa-
tial maps and spend more time in the quadrant containing the hid-
den platform [108], however once a spatial map has been formed
these mice have difﬁculty learning the position of a relocated plat-
form [6]. The redundancy of RyR expression, speciﬁcally in the hip-
pocampus has thus far made it difﬁcult to study the effects of
deletion of any one isoform on neuronal plasticity and LTP. The
generation of brain speciﬁc RyR1 and RyR2 knockouts crossed with
RyR3 deﬁcient mice will help overcome this problem.
RyR3 may also play a role in fear conditioning through its ability
to activate CaMKII. During the retrieval stages of contextual fear
conditioning hippocampal activity of CaMKIIa and CaMKIIb in-
creases in control mice but not in RyR3 deﬁcient mice. Functionally
RyR3 knockout mice have higher locomotor activity after contex-
tual fear conditioning and also spend more time in the open arms
of the elevated plus maze [109] suggesting defects in fear
conditioning.
Neurons are not the only cells in the brain that express RyRs.
Astrocytes, which play key roles in extracellular ion balance,
wound healing, inﬂammation, and glial scar formation, express
RyR3 but not RyR1 or RyR2 [110]. Astrocyte motility, measured
using the in-vitro wound healing assay, is impaired in both astro-
cytes isolated from wild type mice treated with high concentration
of ryanodine that blocks ryanodine receptors as well as in astro-
cytes isolated from RyR3 deﬁcient mice [110].
A role for leaky ryanodine receptors in the pathogenesis of epi-
lepsy has recently been described in the RyR2-R2474S mouse mod-
el of CPVT [90]. Case records from patients with CPVT arrhythmias
include descriptions of syncopal events associated with convulsive
movements. These events were attributed to the arrhythmias caus-
ing rapid compromise of cerebral blood supply, a phenomenon
known as Stokes–Adams attacks. Simultaneous ECG–EEG record-
ings in RyR2-R2474S mice, however, showed seizure activity with-
out any preceding or concurrent arrhythmias suggesting that the
neurological manifestations of the RyR2-R2474S mutation are dis-
tinct from the cardiac phenotype. The brains from these mice are
histologically normal and cells in the principal hippocampal CA3
layer exhibited profound burst activity suggesting that seizure
activity may originate in this region [90]. One question raised by
this study is that RyR2 channels with the R2474S exhibited normal
single channel properties unless they were PKA phosphorylated to
expose the gain-of-function phenotype of this mutation [71].
While strenuous exercise combined with intra-peritoneal injection
of epinephrine is required to induce cardiac arrhythmias, the sei-
zures in RyR2-S2474S mice develop spontaneously without any
apparent b1-adrenergic receptor stimulation. Further investigation
is needed to better understand how RyR2-R2474S mutations can
promote seizures. Additionally, the relationship between RyR
Ca2+ leak, burst activity, and seizure genesis in neurons remains
to be determined.
5. Smooth muscle
Localized RyR mediated SR Ca2+ release events called Ca2+
sparks activate plasmalemmal K+ (BK) channels in smooth muscle,
inducing spontaneous transient outward currents that hyperpolar-
ize the membrane causing muscle relaxation [111]. Smooth muscle
cells isolated from the RyR2 heterozygous knockout mice have re-
duced Ca2+ spark activity [112,113] while cells isolated from the
calstabin2 deﬁcient mice, which have leaky RyR2 [81], have in-
creased spark activity [114] suggesting that RyR2 plays an impor-
tant role in Ca2+ spark activity in smooth muscle.
The role of RyR3 in Ca2+ spark activity is controversial. One
study found that RyR3 deﬁcient mice have reduced smooth muscle
tone associated with an increase in Ca2+ spark activity, suggesting
that RyR3 naturally inhibits Ca2+ sparks [115]. However, other
1962 A. Kushnir et al. / FEBS Letters 584 (2010) 1956–1965studies did not ﬁnd any differences in smooth muscle contractile
properties or Ca2+ spark activity in the RyR3 deﬁcient mice
[104,114]. The differences between these studies may be due to
the types of smooth muscle used (arterial, bladder).
6. Non-excitable cells
Ca2+ handling plays a key role in immune cell functions such as
maturation and migration during immune responses. Human Jur-
kat T-lymphocytes have been reported to express RyR3 [8], how-
ever, despite cellular data suggesting a role of RyR3 in
lymphocyte proliferation RyR3 deﬁcient mice have normal popula-
tions of T- and B-lymphocytes in spleen, thymus, and bone marrow
[104]. Similarly, while RyR1 is reportedly expressed in dendritic
cells, dendritic cells isolated from RyR1 deﬁcient mice exhibit nor-
mal responses to inﬂammatory stimuli and to stimulate a T cell re-
sponse [9].
In the liver, electron microscopy studies reveal that hepatocytes
isolated from RyR1/RyR3 double knockout mice have large accu-
mulations of glycogen granules leading to hepatomegaly [116].
One proposed explanation for this is that these mice have enlarged
adrenal medullas (the adrenal gland modulates glucagon levels via
glucocorticoid secretion) as well as increased numbers of lyso-
somes in medullary cortical cells. However, linking the hepatic
changes to the altered adrenal gland morphology is difﬁcult since
the RyR1, RyR3 and RyR1/RyR3 deﬁcient mice all have similar
adrenal morphologies, yet only the RyR1/RyR3 deﬁcient mice dem-
onstrate any liver abnormalities [116].
RyR2 has also been implicated in insulin secretion from pancre-
atic beta cells. Calstabin2 deﬁcient mice have elevated blood glu-
cose levels after glucose injection secondary to impaired insulin
secretion [8]. Beta-cells from these mice are morphologically sim-
ilar to control mice and have normal insulin stores. It is hypothe-
sized that cADPR, which is elevated when glucose metabolism is
increased, competes calstabin2 off of RyR2 resulting in enhanced
open probability of the channel, causing elevations in cytosolic
[Ca2+] that trigger insulin secretion. According to this hypothesis
it is unclear why insulin secretion is reduced rather than elevated
in these mice since the complete absence of calstabin2 should re-
sult in greater SR Ca2+ leak and higher cytosolic [Ca2+], enhancing
the trigger for insulin secretion. More studies aimed at examining
the dynamics of intracellular Ca2+ handling in these cells are
needed to address this issue.
7. Outlook
The development and analysis of genetically engineered RyR
mouse models has led to an explosion in our understanding of
the physiological and pathological relevance of this complex ion
channel. Despite the many answers that these animals have pro-
vided there are many more questions that they can be used to ad-
dress including: (1) what is the physiological role of RyR channels
in smooth muscle, are they involved only in relaxation, or also in
contraction; (2) what is the biological role for RyR1 and RyR2 in
the brain; (3) are RyR channels in pancreatic beta cells a potential
therapeutic target for diabetes; (4) what is the role of RyR channels
in the immune system? Genetically altered mouse models hold the
promise for revealing new understandings of these and many other
questions that can only be addressed using in vivo models.
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